



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/817,374	03/26/2001	Daniel Delorme	106101.139	9679

7590

09/12/2002

Wayne A Keown
500 West Cummings Park
Suite 2900
Woburn, MA 01801

EXAMINER

BALASUBRAMANIAN, VENKATARAMAN

ART UNIT

PAPER NUMBER

1624

DATE MAILED: 09/12/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/817,374

Applicant(s)

DELORME ET AL.

Examiner

Venkataraman Balasubramanian

Art Unit

1624

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-56 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☐ Claim(s) ____ is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☒ Claim(s) 1-56 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on ____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. ____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). ____.
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) ____.
- 6) ☐ Other: _____.

DETAILED ACTION

Claims 1-56 are pending.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-4, 6-21, 23-33, 35-39, 42-44, 47-49 and 52-56 drawn to compound of formula 1, 2 and 3, wherein the Cy=heterocyclic group which is a furan and benzofuran, group classified in class 549, subclasses 462, 491, class 514 subclasses 461, 464 and various other classes/subclasses depending upon the choice of the other heterocyclic group.
- II. Claims 1-4, 6-21, 23-33, 35-39, 42-44, 47-49 and 52-56 drawn to compound of formula 1, 2 and 3, wherein the Cy=heterocyclic group which is a thiophene, benzothiophene classified in class 549, subclasses 49, 74, 75, 76, class 514, subclasses 438, 443 and various classes/ subclasses various depending upon the choice of the other heterocyclic group.
- III. Claims 1-4, 6-21, 23-33, 35-39, 42-44, 47-49 and 52-56 drawn to compound of formula 1, 2 and 3, wherein the Cy=heterocyclic group which is a indole, classified in class 548, subclass 469, class 514, subclass 415 and various classes/subclasses depending upon the choice of the heterocyclic other group.
- IV. Claims 1-39, 42-44, 47-49 and 52-56 drawn to compound of formula 1, 2 and 3, wherein the Cy= heterocyclic group which is a pyridine, quinoline, isoquinoline, and piperdine group classified in class 546, subclasses

268.1, 290, 152, 139, 184, 192, class 514, subclasses 345, 349, 311, 312, 313, 314, 307, 309, 310, 315 and various other classes/subclasses depending upon the choice of the heterocyclic group.

- V. Claims 1-4, 6-23, 30-33, 35-39, 42-44, 47-49 and 52-56 drawn to compound of formula 1, 2 and 3, wherein the Cy= heterocyclic group which is a thiazole group classified in class 548, subclasses 184, 185, class 514, subclasses 369, 370 and various other classes /subclasses depending upon the choice of the heterocyclic group.
- VI. Claims 1-39, 42-44, 47-49 and 52-56, drawn to compound of formula 1, 2 and 3, wherein the Cy= heterocyclic group which is a morpholine group classified in class 544, subclasses 106, 111, class 514, subclasses 231.2, 231.5.
- VII. Claims 1-39, 42-44, 47-49, 52-56, drawn to compound of formula 1, 2 and 3, wherein the Cy= heterocyclic group which is a piperazine group classified in class 544, subclasses 358, 359, class 514, subclasses 252.12, 252.13.
- VIII. Claims 1-4, 6-33, 35-39, 41-44, 46-49, and 51-56, drawn to compound of formula 1, 2 and 3, wherein the Cy= heterocyclic group which is a quinazolinone group classified in class 544, subclass 287, class 514, subclass 259.
- IX. Claims 1-4, 6-33, 35-39, 41-44, 46-49, and 51-56, drawn to compound of formula 1, 2 and 3, wherein the Cy= heterocyclic group which is a

benzotriazinone group classified in class 544, subclass 180 class 514, subclass 241.

- X. Claims 1-4, 6-33, 36-39, 42-44, 47-49 and 52-56, drawn to compound of formula 1, 2 and 3, wherein the Cy= heterocyclic group which is a phthalimide group classified in class 548, subclass 473, class 514, subclass 417, and various other classes/subclasses depending upon the choice of the other heterocyclic group.
- XI. Claims 1-4, 6-33, 36-39, 42-44, 47-49 and 52-56, drawn to compound of formula 1, 2 and 3, wherein the Cy= heterocyclic group which is a dioxobenzoisoquinoline group classified in class 546, subclass 101, class 514, subclass 290 and various other classes/subclasses depending upon the choice of the other heterocyclic group.
- XII. Claims 1-4, 7-33, 35-39, 42-44, 47-49, 52-56, drawn to compound of formula 1, 2 and 3, wherein the Cy= heterocyclic group not provided for in the above groups I-XI, classified in classes/subclasses various depending upon the choice of the heterocyclic group.
- XIII. Claims 1-4, 6-33, 35-39, 42-44, 47-49, and 52-56, drawn to compound of formula 1, 2 and 3, wherein the Cy= cycloalkyl group which is a classified in classes/subclasses various depending upon the choice of the heterocyclic group and other functional groups.
- XIV. Claims 1-33, 35-39, 41-50, 52-56 drawn to compound of formula 1, 2 and 3, wherein the Cy= aryl group classified in classes/subclasses various

depending upon the choice of the heterocyclic group and other functional groups.

If group XII is elected applicants should elect a specific heterocyclic group with choice of hetero atoms, number of hetero atoms, nature of the ring and ring size for examination.

The inventions are distinct, each from the other because of the following reasons:

Inventions 1 through XIV are independent and distinct from each other because they are directed to structurally dissimilar compounds that lack common core such as furan, benzofuran, thiophene benzothiophene, indole, pyridine, quinoline, isoquinoline thiazole, morpholine, piperazine, quinazolinone, benzotriazinone, phthalimide, dioxobenzoisoquinoline, cycloalkyl, aryl etc. Consequently, the groups have different classifications and require separate prior art searches. They can be made and used independently. Art, which may render obvious or anticipate one of the groups would not necessarily do the same for the other group. Each can support a patent, as the compounds of each group are capable of being utilized alone not in combination with other members listed in the Markush group. In addition searching all these heterocyclic groups would be of serious search burden given the limited time available per application.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

This application contains claims directed to the following patentably distinct species of the claimed invention: See claims 40, 41, 45, 46, 50, and 51.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1-39, 42-44, 47-49 and 52-56 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

In view of distinct nature of each invention, the restriction is set forth in writing.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Conclusion

Any inquiry concerning this communication from the examiner should be addressed to Venkataraman Balasubramanian (Bala) whose telephone number is (703) 305-1674. The examiner can normally be reached on Monday through Thursday from 8.00 AM to 6.00 PM. The Supervisory Patent Examiner (SPE) of the art unit 1624 is Mukund Shah whose telephone number is (703) 308-4716. The fax phone number for the organization where this application or proceeding is assigned (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.


Venkataraman Balasubramanian

9/10/2002.